Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STUART H COHEN

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1043290455
CMS profile
92012
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$9,413.35

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $7,800.00 2
PFIZER INC. $1,613.35 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STUART H COHEN

NPI 1043290455 · CMS profile ID 92012

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043290455?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STUART H COHEN, NPI 1043290455, CMS profile ID 92012. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043290455?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STUART H COHEN, NPI 1043290455, CMS profile ID 92012. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043290455?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STUART H COHEN, NPI 1043290455, CMS profile ID 92012, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1043290455?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $9,413.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $1,480.0012/04/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050523621 CMS
PFIZER INC. $133.3510/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049567487 CMS
ModernaTX, Inc. $3,900.0010/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056977223 CMS
ModernaTX, Inc. $3,900.0010/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056977239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $12.70 1
PY2021 $1,209.35 3
PY2023 $9,413.35 4
PY2024 $1,236.34 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,103.03 26
PY2024 Principal investigator $398,042.05 23
PY2023 Principal investigator $282,460.56 40
PY2022 Principal investigator $308,819.56 68
PY2021 Principal investigator $475,681.35 25
PY2020 Principal investigator $354,189.73 100
PY2019 Principal investigator $195,701.36 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $4,022.20 11/22/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691502471
Principal investigator 1 Merck Sharp & Dohme Corporation $117.20 11/21/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691510799
Principal investigator 1 Gilead Sciences, Inc. $1,383.00 11/20/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676371307
Principal investigator 1 Merck Sharp & Dohme Corporation $437.04 11/20/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 691513565
Principal investigator 1 Gilead Sciences, Inc. $1,383.00 10/23/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676371299
Principal investigator 1 PFIZER INC. $1,556.10 10/23/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671673513
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 10/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691515403
Principal investigator 1 Merck Sharp & Dohme Corporation $0.36 10/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691522341
Principal investigator 1 Merck Sharp & Dohme Corporation $126.60 10/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691522345
Principal investigator 1 Merck Sharp & Dohme Corporation $2.48 10/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691522349
Principal investigator 1 Merck Sharp & Dohme Corporation $24.22 10/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691522353
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 10/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691522358
Principal investigator 1 Merck Sharp & Dohme Corporation $0.16 10/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691528023
Principal investigator 1 Merck Sharp & Dohme Corporation $0.16 10/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691528027
Principal investigator 1 Merck Sharp & Dohme Corporation $2,643.80 10/02/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691430005
Principal investigator 1 Merck Sharp & Dohme Corporation $776.16 09/27/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691507901
Principal investigator 1 Merck Sharp & Dohme Corporation $3,400.00 09/18/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 691503503
Principal investigator 1 Merck Sharp & Dohme Corporation $15,000.00 09/13/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 691486161
Principal investigator 1 Merck Sharp & Dohme Corporation $282.72 09/05/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 691477197
Principal investigator 1 Merck Sharp & Dohme Corporation $4,025.46 09/05/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 691477201
Principal investigator 1 Merck Sharp & Dohme Corporation $655.56 09/05/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 691481695
Principal investigator 1 Merck Sharp & Dohme Corporation $2,682.40 08/28/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691430009
Principal investigator 1 PFIZER INC. $3,092.44 08/14/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671676579
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691482425
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691482435
Principal investigator 1 Merck Sharp & Dohme Corporation $47.00 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691482817
Principal investigator 1 Merck Sharp & Dohme Corporation $41.50 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691503537
Principal investigator 1 Merck Sharp & Dohme Corporation $41.50 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691503889
Principal investigator 1 Merck Sharp & Dohme Corporation $443.10 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691503893
Principal investigator 1 Merck Sharp & Dohme Corporation $47.00 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691503897
Principal investigator 1 Merck Sharp & Dohme Corporation $6.46 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691503901
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691504232
Principal investigator 1 Merck Sharp & Dohme Corporation $0.64 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691505683
Principal investigator 1 Merck Sharp & Dohme Corporation $1.44 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691505685
Principal investigator 1 Merck Sharp & Dohme Corporation $1.76 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691505689
Principal investigator 1 Merck Sharp & Dohme Corporation $11.56 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691505693
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691505703
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691505705
Principal investigator 1 Merck Sharp & Dohme Corporation $24.22 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691505709
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691505713
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691506046
Principal investigator 1 Merck Sharp & Dohme Corporation $61.84 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691507887
Principal investigator 1 Merck Sharp & Dohme Corporation $7.44 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691507891
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691507895
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691538865
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691538867
Principal investigator 1 Merck Sharp & Dohme Corporation $41.50 08/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691539213
Principal investigator 1 Merck Sharp & Dohme Corporation $5,642.80 07/26/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691485414
Principal investigator 1 PFIZER INC. $218.45 07/24/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642211
Principal investigator 1 PFIZER INC. $1,600.00 07/24/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642357
Principal investigator 1 Merck Sharp & Dohme Corporation $910.80 07/18/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691507905
Principal investigator 1 Merck Sharp & Dohme Corporation $13,245.50 07/03/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691430001
Principal investigator 1 PFIZER INC. $1,767.36 07/02/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642405
Principal investigator 1 PFIZER INC. $675.11 06/26/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642209
Principal investigator 1 Gilead Sciences, Inc. $700.00 06/24/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676371293
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 06/19/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 691344771
Principal investigator 1 PFIZER INC. $776.25 06/19/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642275
Principal investigator 1 PFIZER INC. $3,285.00 06/19/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642361
Principal investigator 1 PFIZER INC. $882.00 06/19/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642403
Principal investigator 1 PFIZER INC. $800.00 06/19/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642407
Principal investigator 1 PFIZER INC. $600.00 06/19/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642459
Principal investigator 1 Merck Sharp & Dohme Corporation $61.84 06/10/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691403467
Principal investigator 1 Merck Sharp & Dohme Corporation $105.48 06/10/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691404605
Principal investigator 1 PFIZER INC. $23,400.00 06/05/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642359
Principal investigator 1 Merck Sharp & Dohme Corporation $4,795.30 05/31/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691317715
Principal investigator 1 PFIZER INC. $2,906.32 05/29/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623037
Principal investigator 1 PFIZER INC. $1,600.00 05/29/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623039
Principal investigator 1 PFIZER INC. $2,000.00 05/29/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623055
Principal investigator 1 Merck Sharp & Dohme Corporation $91.96 05/24/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691484638
Principal investigator 1 Merck Sharp & Dohme Corporation $949.20 05/24/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691539215
Principal investigator 1 Gilead Sciences, Inc. $1,726.00 05/22/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676371287
Principal investigator 1 PFIZER INC. $2,899.13 05/08/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623053
Principal investigator 1 Merck Sharp & Dohme Corporation $1,577.70 05/01/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691319485
Principal investigator 1 PFIZER INC. $2,025.33 05/01/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623065
Principal investigator 1 Merck Sharp & Dohme Corporation $1,600.00 04/10/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691317709
Principal investigator 1 PFIZER INC. $12,043.61 04/10/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627293
Principal investigator 1 Shire North American Group Inc $1,600.00 04/09/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTIONS THAT ARE RESISTANT OR REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR IN TRANSPLANT RECIPIENTS No dispute reported 06/30/2026 637706443
Principal investigator 1 Merck Sharp & Dohme Corporation $314.85 04/05/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 691343643
Principal investigator 1 Merck Sharp & Dohme Corporation $3,197.00 03/29/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691317711
Principal investigator 1 PFIZER INC. $3,663.40 03/27/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671623035
Principal investigator 1 PFIZER INC. $893.56 03/20/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627291
Principal investigator 1 Merck Sharp & Dohme Corporation $759.36 03/19/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691295023
Principal investigator 1 Gilead Sciences, Inc. $1,600.00 03/11/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676371278
Principal investigator 1 PFIZER INC. $10,493.51 03/04/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627227
Principal investigator 1 Merck Sharp & Dohme Corporation $3,476.70 02/27/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691317713
Principal investigator 1 Merck Sharp & Dohme Corporation $183.92 02/27/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691536827
Principal investigator 1 PFIZER INC. $6,449.42 02/13/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616375
Principal investigator 1 Shire North American Group Inc $2,038.93 02/12/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTIONS THAT ARE RESISTANT OR REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR IN TRANSPLANT RECIPIENTS No dispute reported 06/30/2026 637706419
Principal investigator 1 AbbVie, Inc. $2,331.00 02/04/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
M16-133 No dispute reported 06/30/2026 647624203
Principal investigator 1 PFIZER INC. $1,350.22 02/04/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616533
Principal investigator 1 Merck Sharp & Dohme Corporation $15,150.80 01/23/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691308943
Principal investigator 1 PFIZER INC. $10,498.28 01/16/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671616121
Principal investigator 1 Merck Sharp & Dohme Corporation $45.98 01/15/2019 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 691295017